Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 1/2 1

Status

Completed 3Active not recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Tumor-Agnostic 1Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Neoplasms 2Parkinson Disease 4, Autosomal Dominant Lewy Body 1Endometrial Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 37Carboplatin 31Cisplatin 30Paclitaxel 23Nivolumab 21Pemetrexed 21Dexamethasone 18Gemcitabine 18Ipilimumab 15Docetaxel 13Fluorouracil 13Capecitabine 12Rituximab 12Cyclophosphamide 10Cytarabine 10Trastuzumab 9atezolizumab 9daratumumab 9olaparib 9130-nm albumin-bound paclitaxel 8Lenalidomide 8Prednisone 8durvalumab 8trastuzumab deruxtecan 8Bevacizumab 7Bortezomib 7Fulvestrant 7Oxaliplatin 7Vinorelbine 7cabozantinib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Has results × Has announcements × lenvatinib × Clear all
NCT03517449 2026-03-19

MK-3475-775

Eisai Inc.

Phase 3 Completed
827 enrolled 34 charts 1 FDA
Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Endometrial Neoplasms

NCT02811861 2026-02-23

CLEAR

Eisai Inc.

Phase 3 Active not recruiting
1,069 enrolled 12 charts 1 FDA
Genitourinary

Carcinoma, Renal Cell

NCT02501096 2023-07-20

A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid Tumors

Eisai Inc.

Phase 1/2 Completed
357 enrolled 28 charts 1 FDA
Tumor-Agnostic

Neoplasms

NCT01761266 2022-04-05

A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma

Eisai Inc.

Phase 3 Completed
954 enrolled 19 charts 1 FDA
Gastrointestinal

Carcinoma, Hepatocellular, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡